IL123600A - History of quinolone - 2 (1H), their preparation and pharmaceutical preparations containing them - Google Patents

History of quinolone - 2 (1H), their preparation and pharmaceutical preparations containing them

Info

Publication number
IL123600A
IL123600A IL12360096A IL12360096A IL123600A IL 123600 A IL123600 A IL 123600A IL 12360096 A IL12360096 A IL 12360096A IL 12360096 A IL12360096 A IL 12360096A IL 123600 A IL123600 A IL 123600A
Authority
IL
Israel
Prior art keywords
group
equal
formula
mmol
compounds
Prior art date
Application number
IL12360096A
Other languages
English (en)
Hebrew (he)
Other versions
IL123600A0 (en
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9510815A external-priority patent/FR2738822B1/fr
Priority claimed from FR9511083A external-priority patent/FR2739100B1/fr
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of IL123600A0 publication Critical patent/IL123600A0/xx
Publication of IL123600A publication Critical patent/IL123600A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL12360096A 1995-09-15 1996-09-12 History of quinolone - 2 (1H), their preparation and pharmaceutical preparations containing them IL123600A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9510815A FR2738822B1 (fr) 1995-09-15 1995-09-15 Derives de 4-(omega-(4-(thieno(3,2-c)pyridin-4-yl)piperazin- 1-yl)alkyl)quinolein-2(1h)-one, leur preparation et leur application en therapeutique
FR9511083A FR2739100B1 (fr) 1995-09-21 1995-09-21 Derives de 4-(omega-(4-(4-fluorobenzoyl)piperidin-1-yl)- alkyl)quinolein-2(1h)-one, leur preparation et leur application en therapeutique
PCT/FR1996/001401 WO1997010238A1 (fr) 1995-09-15 1996-09-12 Derives de quinolein-2(1h)-one comme antagonistes de la serotonine

Publications (2)

Publication Number Publication Date
IL123600A0 IL123600A0 (en) 1998-10-30
IL123600A true IL123600A (en) 2001-05-20

Family

ID=26232206

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12360096A IL123600A (en) 1995-09-15 1996-09-12 History of quinolone - 2 (1H), their preparation and pharmaceutical preparations containing them

Country Status (30)

Country Link
US (1) US5958924A (ru)
EP (1) EP0850235B1 (ru)
JP (1) JP3335362B2 (ru)
KR (1) KR100422850B1 (ru)
CN (1) CN1094490C (ru)
AR (1) AR003996A1 (ru)
AT (1) ATE187172T1 (ru)
AU (1) AU715879B2 (ru)
BG (1) BG63779B1 (ru)
BR (1) BR9610579A (ru)
CA (1) CA2228038C (ru)
CO (1) CO4750663A1 (ru)
CZ (1) CZ288149B6 (ru)
DE (1) DE69605430T2 (ru)
DK (1) DK0850235T3 (ru)
EE (1) EE04116B1 (ru)
ES (1) ES2142089T3 (ru)
GR (1) GR3032618T3 (ru)
HK (1) HK1014868A1 (ru)
HU (1) HU222745B1 (ru)
IL (1) IL123600A (ru)
NO (1) NO323841B1 (ru)
NZ (1) NZ318436A (ru)
PL (1) PL184808B1 (ru)
RU (1) RU2167874C2 (ru)
SI (1) SI0850235T1 (ru)
SK (1) SK282222B6 (ru)
TR (1) TR199800464T1 (ru)
UA (1) UA44332C2 (ru)
WO (1) WO1997010238A1 (ru)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3335362B2 (ja) * 1995-09-15 2002-10-15 サノフィ―サンテラボ キノレイン−２（１ｈ）−オン誘導体セロトニンアンタゴニスト
FR2761071B1 (fr) * 1997-03-20 1999-12-03 Synthelabo Derives de quinolein-2(1h)-one et de dihydroquinolein-2(1h)- one, leur preparation et leur application en therapeutique
FR2761067B1 (fr) * 1997-03-20 1999-04-23 Synthelabo Derives de quinolein-2-(1h)-one, leur preparation et leur application en therapeutique
FR2797874B1 (fr) * 1999-08-27 2002-03-29 Adir Nouveaux derives de la pyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN1395575A (zh) 2000-01-20 2003-02-05 卫材株式会社 新的哌啶化合物及其药物
FR2812548B1 (fr) * 2000-08-01 2002-09-20 Sanofi Synthelabo Utilisation de derives de quinolein-2(1h)-one ou un de leurs sels pharmaceutiquement acceptable pour la preparation d'un medicament destine au traitement de l'insuffisance renale
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
FR2909670B1 (fr) * 2006-12-12 2010-07-30 Sanofi Aventis Derive fluore de quinoleine-2(1h)-one,son procede de preparation et son utilisation comme intermediaire de synthese
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
AU2008297876B2 (en) 2007-09-14 2011-07-07 Addex Pharma S.A. 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
BRPI0816767B8 (pt) 2007-09-14 2021-05-25 Addex Pharmaceuticals Sa composto 4-fenil-3,4,5,6-tetra-hidro-2h,1'h-[1,4']bipiridi¬nil-2'-onas 1',3'-dissubstituídas, composição farmacêutica e uso dos mesmos
AU2009289784B2 (en) 2008-09-02 2012-03-22 Addex Pharma S.A. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
ES2424393T3 (es) * 2008-10-02 2013-10-01 Taisho Pharmaceutical Co., Ltd. Derivado de 7-piperidinalquil-3,4-dihidroquinolona
WO2010060589A1 (en) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US8946205B2 (en) 2009-05-12 2015-02-03 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
MY161325A (en) 2009-05-12 2017-04-14 Janssen Pharmaceuticals Inc 1, 2, 4-triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
CN103261195B (zh) 2010-11-08 2015-09-02 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
PL2649069T3 (pl) 2010-11-08 2016-01-29 Janssen Pharmaceuticals Inc Pochodne 1,2,4-triazolo[4,3-a]pirydyny i ich zastosowanie jako dodatnich allosterycznych modulatorów receptorów mGluR2
AU2011328203B2 (en) 2010-11-08 2015-03-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
KR102461134B1 (ko) 2014-01-21 2022-10-28 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
UA121965C2 (uk) 2014-01-21 2020-08-25 Янссен Фармацевтика Нв Комбінації, які містять позитивні алостеричні модулятори або ортостеричні агоністи метаботропного глутаматергічного рецептора 2 підтипу, та їх застосування
JP6974331B2 (ja) 2016-02-05 2021-12-01 デナリ セラピューティクス インコーポレイテッドDenali Therapeutics Inc. 化合物、組成物及び方法
HUE058802T2 (hu) 2016-12-09 2022-09-28 Denali Therapeutics Inc RIPK1 inhibitorokként alkalmas vegyületek
CN108707109A (zh) * 2018-08-29 2018-10-26 常州沃腾化工科技有限公司 一种2-甲氧基-4-三氟甲基吡啶-3-磺酰氯的制备方法
AU2023206890A1 (en) 2022-01-12 2024-08-22 Denali Therapeutics Inc. Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1278792C (en) * 1985-05-06 1991-01-08 Joseph P. Yevich Antipsychotic fused-ring pyridinylpiperazine derivatives
KR910006138B1 (ko) * 1986-09-30 1991-08-16 에자이 가부시끼가이샤 환상아민 유도체
FR2644786B1 (fr) * 1989-03-21 1993-12-31 Adir Cie Nouveaux derives fluoro-4 benzoiques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
JP3335362B2 (ja) * 1995-09-15 2002-10-15 サノフィ―サンテラボ キノレイン−２（１ｈ）−オン誘導体セロトニンアンタゴニスト

Also Published As

Publication number Publication date
GR3032618T3 (en) 2000-05-31
CO4750663A1 (es) 1999-03-31
WO1997010238A1 (fr) 1997-03-20
NO981141D0 (no) 1998-03-13
ATE187172T1 (de) 1999-12-15
AR003996A1 (es) 1998-09-30
CA2228038A1 (en) 1997-03-20
ES2142089T3 (es) 2000-04-01
BG63779B1 (bg) 2002-12-29
BG102316A (en) 1999-03-31
HK1014868A1 (en) 1999-10-08
NZ318436A (en) 1999-02-25
TR199800464T1 (xx) 1998-05-21
UA44332C2 (uk) 2002-02-15
AU715879B2 (en) 2000-02-10
EP0850235B1 (fr) 1999-12-01
EE04116B1 (et) 2003-08-15
SK34698A3 (en) 1998-08-05
CZ288149B6 (en) 2001-05-16
PL184808B1 (pl) 2002-12-31
KR19990044666A (ko) 1999-06-25
HUP9802940A3 (en) 2001-11-28
JP3335362B2 (ja) 2002-10-15
DE69605430D1 (de) 2000-01-05
SK282222B6 (sk) 2001-12-03
NO323841B1 (no) 2007-07-09
KR100422850B1 (ko) 2004-07-23
EP0850235A1 (fr) 1998-07-01
SI0850235T1 (en) 2000-04-30
AU6991996A (en) 1997-04-01
IL123600A0 (en) 1998-10-30
CA2228038C (en) 2009-04-21
CN1202168A (zh) 1998-12-16
CZ78698A3 (cs) 1998-06-17
JPH11514982A (ja) 1999-12-21
HUP9802940A2 (hu) 1999-05-28
BR9610579A (pt) 1999-07-06
HU222745B1 (hu) 2003-09-29
RU2167874C2 (ru) 2001-05-27
PL325467A1 (en) 1998-07-20
DK0850235T3 (da) 2000-05-29
CN1094490C (zh) 2002-11-20
US5958924A (en) 1999-09-28
DE69605430T2 (de) 2000-07-13
NO981141L (no) 1998-05-15
MX9802028A (es) 1998-09-30
EE9800089A (et) 1998-10-15

Similar Documents

Publication Publication Date Title
IL123600A (en) History of quinolone - 2 (1H), their preparation and pharmaceutical preparations containing them
KR100196559B1 (ko) 안지오텐신ii 길항작용을 함유하는 피리딘 유도체
JP2730612B2 (ja) ８‐クロロ‐１１‐〔１‐〔（５‐メチル‐３‐ピリジル）メチル〕‐４‐ピペリジリデン〕‐６，１１‐ジヒドロ‐５Ｈ‐ベンゾ〔５，６〕シクロヘプタ〔１，２‐ｂ〕ピリジン
JP3599350B2 (ja) 新規なｎ−置換キノリン誘導体、それらの製造法、それらの薬剤としての使用及びそれらを含有する製薬組成物
BG107672A (bg) Антагонисти на метаботропни глутамат рецептори
PL165502B1 (pl) Sposób wytwarzania nowych pochodnych aminopirymidyny PL PL PL PL PL
JPH0676403B2 (ja) 新規なベンゾ［５，６ シクロヘプタ［１，２−ｂ ピリジン誘導体及びこれを含有する抗アレルギー剤
KR100224135B1 (ko) 퀴놀린 또는 퀴나졸린 유도체, 그 제조 및 용도
JP2005529843A (ja) トリアゾロ［４，３−ａ］ピリド［２，３−ｄ］ピリミジン−５−オン、それらを含有する組成物、その製造方法及び使用
CA3016830A1 (en) Crystalline forms of mesylate salt of pyridinyl amino pyrimidine derivative, preparation methods therefor, and applications thereof
EP3240783B1 (en) New benzimidazole derivatives as antihistamine agents
JPS6346077B2 (ru)
JPS60214778A (ja) Ν置換３，４−ジヒドロピリミジン誘導体ならびにその製造法および用途
WO2006112828A1 (en) Azaindole derivatives as inhibitors of p38 kinase
EP0743943B1 (en) Pyridyl imidazole derivatives and processes for the preparation thereof
JPH07267951A (ja) アンジオテンシンｉｉ拮抗剤としての新規イミダゾピリジン誘導体
MXPA98002028A (en) Quinolein-2 (1h) -ona derivatives as seroton antagonists
JP2860688B2 (ja) インドール誘導体
JPH0625250A (ja) チエノ〔３，４−ｄ〕イミダゾール誘導体、その製造法およびそれを含有する循環器官用剤
EP0265947B1 (en) Dihydropyridine derivatives, process for their preparation, pharmaceutical composition and use
IE913102A1 (en) Therapeutic agents
FR2738822A1 (fr) Derives de 4-(omega-(4-(thieno(3,2-c)pyridin-4-yl)piperazin- 1-yl)alkyl)quinolein-2(1h)-one, leur preparation et leur application en therapeutique
CN116848117A (zh) 作为Wee-1抑制剂的稠环化合物
JP2585497B2 (ja) アンジオテンシン２拮抗性ピリジン誘導体
FR2739100A1 (fr) Derives de 4-(omega-(4-(4-fluorobenzoyl)piperidin-1-yl)- alkyl)quinolein-2(1h)-one, leur preparation et leur application en therapeutique

Legal Events

Date Code Title Description
FF Patent granted
NE Application for restoration - patent lapsed through non-payment of renewal fees (section 60, patents law, 5727-1967)
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees